Barclays raised the firm’s price target on Bruker (BRKR) to $45 from $40 and keeps an Overweight rating on the shares post the Q3 report. The company’s end markets remain relatively stable but soft, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker Corporation Reports Q3 2025 Financial Results
- Cautious Optimism for Bruker: Hold Rating Amid Uncertain Sustained Growth
- Bruker upgraded to Hold from Sell at Nephron Research
- Morning Movers: Kenvue surges, Kimberly-Clark sinks after tie up
- Bruker cuts FY25 EPS view to $1.85-$1.90 from $1.95-$2.05, consensus $1.94